A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
第1相
完了
NCT06262477
| 対象疾患 | Healthy Volunteer |
|---|
| 相 | 第1相 |
|---|
| スポンサー | Biogen |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 300 名 |
|---|
| 介入（薬剤） | BIIB800, Actemra |
|---|
| 開始日 | 2024年1月2日 |
|---|
| 完了日 | 2024年9月25日 |
|---|
| 結果公開日 | 2025年10月6日 |
|---|
概要
The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.
Maximum Observed Serum Concentration (Cmax) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · micrograms per milliter (μg/mL)
| BIIB800 | 10.5 ± 43.3 micrograms per milliter (μg/mL) |
|---|
| Actemra | 10.0 ± 41.3 micrograms per milliter (μg/mL) |
|---|
| Ratio of GLSM | 1.05 (95% CI 0.974–1.13) |
|---|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · hours (h)*μg/ mL
| BIIB800 | 2380 ± 44.9 hours (h)*μg/ mL |
|---|
| Actemra | 2240 ± 41.1 hours (h)*μg/ mL |
|---|
| Ratio of GLSM | 1.07 (95% CI 0.988–1.15) |
|---|
Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · h*μg/ mL
| BIIB800 | 2120 ± 45.9 h*μg/ mL |
|---|
| Actemra | 2000 ± 44.0 h*μg/ mL |
|---|
| Ratio of GLSM | 1.06 (95% CI 0.985–1.15) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。